Leqembi could cost Medicare up to $17.8B

(By Rylee Wilson for Becker’s Hospital Review)

Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease, will cost Medicare billions each year, according to an analysis from KFF. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org